News
Click here for news in Danish.
December 21, 2018 | Company Announcements
Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox VaccineNovember 13, 2018 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramNovember 09, 2018 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2018 November 02, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic CancersNovember 01, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Trial of BN-Brachyury for the Treatment of Chordoma November 01, 2018 | Company Announcements
Henrik Juuel Joins Bavarian Nordic as Chief Financial OfficerSeptember 19, 2018 | Press Releases
Bavarian Nordic Delivers Smallpox Vaccine to England in Response to Current Monkeypox CasesSeptember 18, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder CancerAugust 21, 2018 | Press Releases
Importance of Smallpox Vaccination Highlighted in Biopreparedness Exercise August 16, 2018 | Company Announcements
Bavarian Nordic Announces First Half 2018 Results August 09, 2018 | Company Announcements
Bavarian Nordic Granted EUR 30 Million Loan from The European Investment BankAugust 08, 2018 | Company Announcements
Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV VaccineJuly 11, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal CancerJune 07, 2018 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise May 31, 2018 | Company Announcements
Bavarian Nordic Announces Appointment of Henrik Juuel as Chief Financial OfficerMay 24, 2018 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2018 May 16, 2018 | Press Releases
Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting May 02, 2018 | Company Announcements
Bavarian Nordic Receives FDA Orphan Drug Designation for BN-Brachyury for the Treatment of ChordomaApril 17, 2018 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held April 17, 2018March 26, 2018 | Company Announcements
Bavarian Nordic A/S – Notice Convening Ordinary General Meeting March 16, 2018 | Company Announcements
Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis VirusMarch 12, 2018 | Company Announcements
Bavarian Nordic Awards Restricted Stock Units to Executive ManagementMarch 12, 2018 | Company Announcements
Bavarian Nordic Announces Annual Report 2017 March 08, 2018 | Company Announcements
Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal CancerMarch 06, 2018 | Company Announcements
Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine